Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis
A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 177 participants.
Also called NCT05804903
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 177 participants
- Sponsor
- NVT GmbH
- Registry
-
NCT05804903
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Finland, Germany, Poland, Spain, Switzerland
- Registry status
- Suspended
Technical summary
Registry record NCT05804903. Allocation not applicable; no masking; primary purpose treatment. Start 2023-11-24 (actual); primary completion 2025-08-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis
- Acronym
- EMPIRE-II
- Condition
- Transcatheter Aortic Valve Implantation
- Intervention (Device)
- (ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
- Lead sponsor
- NVT GmbH
Record details
- Record id
cardio:ct-nct05804903- Content hash
a8b2fa823df4cce659d7a0b7d19633151d76e65311b97879a230ee2ca4547e22